Immunohistochemistry (IHC) Market (2025-2032)
The Immunohistochemistry Market is anticipated to reach $4.08 billion by 2032 at a CAGR of 7.2% from 2025–2032.
- Published
- Sep 2024
- Pages
- 240
- Format
- PDF + Excel
- Report ID
- MRHC - 1041284
- Base year
- 2024
- 2032 · FORECAST
- $4.08B
- 2032
- $4.08B
- CAGR 2025–2032
- 7.2%
2024 baseline · 2025–2032 forecast at 7.2% CAGR · hover a bar for the value
Key highlights
By Offering: In 2025, the Consumables Segment to Dominate the Immunohistochemistry Market
By Method: In 2025, the Avidin-Biotin Complex Segment to Dominate the Immunohistochemistry Market
By Application: In 2025, the Clinical Applications Segment to Dominate the Immunohistochemistry Market
By End User: In 2025, the Hospitals & Diagnostic Laboratories Segment to Dominate the Immunohistochemistry Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 240 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 7.2% |
| Estimated Market Size (Value) | $4.08 billion by 2032 |
| Segments Covered | By Offering · Consumable · Reagents · Fixation Reagents · Antigen Retrieval · Buffers · Blocking Reagents · Antibodies · Control Reagents · Chromogenic Substrates · Counterstain · Other Accessories · Equipment · Staining System · Imaging Systems · Slide Scanners · Tissue Microarrays · Services & Software · (Note : Other accessories include glass slides, racks, & vials, mounting media, and organic solvents.) · By Method · Avidin-Biotin Complex · Polymer-Based Immunohistochemistry · Catalyzed Signal Amplification (CSA) · Fluorescyl-tyramide Amplification · Improved Catalyzed Signal Amplification (iCSA) · Multi-Staining Immunohistochemistry · Labeled Streptavidin Biotin (LSAB) · PAP Method · By Process · Sample Preparation · Antigen Retrieval · Background Blocking · Target Detection · Sample Visualization · By Application · Research and Other Applications · Drug Discovery · Agriculture & Animal Research · Other Applications · Clinical Applications · Reproductive Health · Oncology · Infectious Disease · Other Clinical Applications · (Note1: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.) · (Note2: Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.) · By End User · Pharmaceutical & Biotechnology Companies · Hospitals & Diagnostic Laboratories · Academic Institutes & Research Centers · Other End Users · (Note : Other end users include forensic laboratories and transfusion laboratories.) |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Eagle Biosciences, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S), Cell Signaling Technology, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio SB Inc. (U.S.), Biocare Medical, LLC. (U.S.), Bio-Genex Laboratories (U.S.), and CANDOR Bioscience GmbH |
Report overview
Segments covered: offering, consumable, reagent, fixation reagent, antigen retrieval, buffer, blocking reagent, antibody, control reagent, chromogenic substrate, counterstain, other accessory, equipment, staining system, imaging system, slide scanner, tissue microarray, services & software, method, avidin-biotin complex, polymer-based immunohistochemistry, fluorescyl-tyramide amplification, multi-staining immunohistochemistry, pap method, process, sample preparation, background blocking, target detection, sample visualization, application, research, other application, drug discovery, agriculture & animal research, clinical application, reproductive health, oncology, infectious disease, other clinical application, end user, pharmaceutical & biotechnology company, hospitals & diagnostic laboratory, academic institutes & research center, other end user. Regions: North America, Europe, Asia-Pacific, Latin America.
A multitude of factors drives the growth of the immunohistochemistry market. These include the increasing prevalence of chronic diseases, particularly among the growing geriatric population, the heightened focus on rare diseases, the growing awareness of the importance of early disease diagnosis, the rising expenditure on research & development, the surging demand for drug discovery & development, the rising incidence of infectious diseases, the mounting funding for research activities, and the increasing healthcare expenditure.
Furthermore, inclination toward personalized medicine, advancements in genomics and proteomics, and increasing automation in immunohistochemistry are expected to offer significant growth opportunities for market growth.
Report infographic
-Market.webp)
Market dynamics
5 factors across 3 forcesRising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease are on the rise globally. Cancer is one of the leading causes of death around the world. For instance, the World Health Organisation (WHO) 2022 report states that about 10 million deaths worldwide in 2020 were attributable to cancer, with 1.80 million of those deaths being caused by lung cancer. An increasing number of people are afflicted with chronic diseases, largely due to societal behaviors, including alcohol and tobacco use, physical inactivity, and bad diets, as well as the aging population. The International Diabetes Federation estimates that 6.7 million deaths worldwide in 2021 will be attributed to diabetes. The need for sophisticated laboratory IHC solutions to aid in the more accurate diagnosis of cancer and other diseases is growing due to the rise in chronic diseases and the aging population, which is less resistant to these conditions.
Increasing Research & Development Expenditure
Pharmaceutical companies are continually focusing on R&D, which is a critical component of medication development procedures. The biotechnology industry also makes significant investments in research & development to meet the growing need for innovation and new medical advances. The increasing number of medicine approvals demonstrates the importance of research and development. For example, according to a report published by the European Commission, the European Union would spend USD 374.1 billion on research and development in 2022, up 7% from 2021 and 47.5% from 2012. Furthermore, nations such as India and China are substantially investing in research and development, which is expected to increase demand for advanced research solutions, which in turn is expected to boost the demand for immunohistochemistry products.
Table of contents
13 chapters · 146 sections · 240 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Consumables | — |
| By Method | Avidin-Biotin Complex | — |
| By Application | Clinical Applications | — |
| By End User | Hospitals & Diagnostic Laboratories | — |
By Offering
- The Consumables Segment to Dominate the Immunohistochemistry Market
- The consumables segment is expected to account for a large share of 68.4% of the immunohistochemistry market.
- The consumables segment is further sub-segmented into reagents, kits, and other accessories.
- Advancements in kits and reagents enable laboratories to perform multiple tests simultaneously.
- Other factors, such as the rising prevalence of chronic diseases and increased genetic and rare disease research by biopharmaceutical companies, contract research organizations, and research laboratories, drive the demand for IHC kits and reagents.
By Method
- The avidin-biotin complex segment is expected to account for the largest share of 30.8% of the immunohistochemistry market.
- The large market share of this segment is attributed to the various advantages offered by avidin-biotin complex, which include resistivity to enzymatic reactions, PH changes, temperature, denaturation, and organic reagents, increased detection efficiency, requiring less primary antibody, and less assay time as compared to other methods.
By Application
- The clinical applications segment is expected to account for the largest share of the immunohistochemistry market.
- The clinical applications segment is further sub-segmented into reproductive health, oncology, infectious disease, and other clinical applications.
- Factors driving the growth of this segment include the increasing incidence of cancer, the rising awareness among healthcare professionals about the advantages of immunohistochemistry testing for treatment purposes, and the increasing number of diagnostic laboratories.
- For instance, cancer is one of the leading causes of death across the globe.
- According to WHO, approximately 400,000 children develop cancer per year in the world, increasing the demand for immunohistochemistry tests for the detection of the disease.
By End User
- The hospitals & diagnostic laboratories segment is expected to account for the largest share of the immunohistochemistry market.
- This segment’s large market share is attributed to the increasing prevalence of cancer, rising healthcare expenditure, and the growing number of hospitals in both developed and developing countries.
- Furthermore, more inclination of patients toward hospitals due to developed infrastructure, availability of skilled professionals, and availability of advanced treatments.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of 38.4% of the immunohistochemistry market. North America's significant market share is attributed to the presence of key immunohistochemistry technology and product providers, high prevalence of chronic and infectious diseases, high awareness regarding early disease diagnosis, growing adoption of advanced diagnostic products, and rising funding activities coupled with novel developments in clinical and research technologies.
Asia-Pacific
Fastest growthMoreover, Asia-Pacific is poised to register the highest CAGR of 13% during the forecast period. This region’s growth is attributed to continuous improvements in healthcare infrastructure, the rising number of hospitals, and increasing government investments in this sector. Accelerated economic growth in many countries of the Asia-Pacific region has relatively increased the focus of various governments on the healthcare sector in terms of increased investments to enhance the accessibility to healthcare facilities and build better healthcare infrastructure. For instance, according to a report published by the Ministry of Finance of India, for the year 2022-2024 Central and State Governments' budget for healthcare is 2.1% of total gross domestic product (GDP).
Competitive landscape
- February 2024
F. Hoffmann-La Roche Ltd (Switzerland) collaborated with Janssen, a division of Johnson & Johnson Pte. Ltd. (U.S.) for precision medicine with various companion diagnostic technologies, which includes digital pathology, immunohistochemistry, next-generation sequencing, immunoassays, and polymerase chain reaction (PCR).
- January 2024
Agilent Technologies, Inc. (U.S.) partnered with Akoya Biosciences, Inc. (U.S) to develop multiplex-immunohistochemistry diagnostic solutions for the analysis of tissue and for commercializing workflow solutions.
- October 2022
F. Hoffmann-La Roche Ltd (Switzerland) launched Anti-PRAME (EPR 20330), a Rabbit Monoclonal Primary Antibody. This antibody is used to identify protein expression in tissue samples.
- F. Hoffmann-La Roche Ltd · Switzerland
- Danaher Corporation (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Merck KGaA · Germany
- Bio-Rad Laboratories Inc. (U.S.)
- Eagle Biosciences, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S)
- Cell Signaling Technology, Inc. (U.S.)
- PerkinElmer, Inc. (U.S.)
- Bio SB Inc. (U.S.)
- Biocare Medical, LLC. (U.S.)
- Bio-Genex Laboratories (U.S.)
- CANDOR Bioscience GmbH · Germany
Frequently asked questions
The global immunohistochemistry market report covers the qualitative analysis and market sizing of offering, method, process, application, and end user. This report involves the analysis of various segments of immunohistochemistry at the regional and country level. The report also provides insights on factors impacting market growth, regulatory analysis, case studies, pricing analysis, regulatory analysis, and Porter’s five forces analysis.
Cite this report
Meticulous Research. (2024). Immunohistochemistry (IHC) Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 1041284). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/immunohistochemistry-market-5967